Clinical Trial Update: A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet [Phase 2, Phase 3]

View source ↗

Summary

This randomized, double-blind Phase 2/3 trial compared simvastatin 20 mg/day to Vytorin (ezetimibe/simvastatin 10/20) in adults with lipid profiles not meeting …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• SIMVASTATIN (SIMVASTATIN)
• Vytorin (ezetimibe/simvastatin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hyperlipidemia | Phase 2, Phase 3 | Status: COMPLETED